PING-ING LEELin T.-Y.Hsieh K.-S.Shyur S.-D.Hsia S.-H.Huang Y.-F.FRANK LEIGH LUHwang B.Chiu N.-C.CHUN-YI LUChi C.-S.Chen P.-Y.LUAN-YIN CHANGJONG-MIN CHENBOR-LUEN CHIANGHuang Y.-C.Lee C.-Y.2020-12-082020-12-0820101875-9572https://www.scopus.com/inward/record.uri?eid=2-s2.0-76749095991&doi=10.1016%2fS1875-9572%2810%2960001-0&partnerID=40&md5=2c94a07265167596d60c7325760bf539https://scholars.lib.ntu.edu.tw/handle/123456789/524936[SDGs]SDG3creatine kinase; immunoglobulin; influenza vaccine; Influenza virus hemagglutinin; oseltamivir; sialidase inhibitor; steroid; virus sialidase; zanamivir; active immunization; antiviral resistance; antiviral therapy; article; avian influenza; bacterial infection; breathing rate; child; child hospitalization; clinical feature; developmental disorder; diarrhea; digestive system function disorder; disease transmission; drug contraindication; drug fever; drug indication; drug megadose; egg allergy; encephalitis; genetic reassortment; human; infection control; influenza; Influenza virus A H1N1; injection site erythema; injection site pain; injection site swelling; laboratory diagnosis; lung complication; lymphocytopenia; mixed infection; neurological complication; oxygenation; pediatrics; personal hygiene; pneumonia; recommended drug dose; reverse transcription polymerase chain reaction; risk factor; screening test; sputum analysis; Staphylococcus aureus; Streptococcus pneumoniae; swine influenza virus; symptom; treatment duration; virus culture; virus shedding; vomiting; Humans; Immunization; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Risk Factorsjournal article10.1016/S1875-9572(10)60001-0202255302-s2.0-76749095991